9606 Share Price Performance
HK$323.60
118.60 (57.85%)
Price HK$323.60
Share Pricen/a
Duality Biotherapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
9606 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Duality Biotherapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -28.79
- 31.81%
- -140.13%
- 5.8%
About 9606
- Founded
- 2019
- Employees
- 231
- CEO
- WebsiteView website
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. The company was incorporated in 2019 and is headquartered in Shanghai, China.
